Cargando…

Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy

Hepatitis B virus (HBV) reactivation can lead to severe acute hepatic failure and death in patients with HBV infection. HBV reactivation (HBVr) most commonly develops in patients undergoing cancer chemotherapy, especially B cell-depleting agent therapy such as rituximab and ofatumumab for hematologi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shih, Chih-An, Chen, Wen-Chi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316946/ https://www.ncbi.nlm.nih.gov/pubmed/34368296 http://dx.doi.org/10.12998/wjcc.v9.i21.5769

Ejemplares similares

Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment
por: Spera, Anna Maria
Publicado: (2022)

Screening and prevention of hepatitis C virus reactivation during chemotherapy
por: Li, Yuan-Rung, et al.
Publicado: (2021)

Hepatitis B virus reactivation in rheumatoid arthritis
por: Wu, Ya-Li, et al.
Publicado: (2022)

Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review
por: Tavakolpour, Soheil, et al.
Publicado: (2016)

Discontinuation of antiviral therapy in chronic hepatitis B patients
por: Medas, Renato, et al.
Publicado: (2021)

Prevention of Hepatitis B reactivation in the setting of immunosuppression
por: Pattullo, Venessa
Publicado: (2016)

Prevention of vertical transmission of hepatitis B virus infection
por: Veronese, Piero, et al.
Publicado: (2021)

Impact of coronavirus disease 2019 on prevention and elimination strategies for hepatitis B and hepatitis C
por: Rehman, Syed Tabish, et al.
Publicado: (2021)

Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics
por: Akiyama, Shintaro, et al.
Publicado: (2021)

Hepatitis B in renal transplant patients
por: Marinaki, Smaragdi, et al.
Publicado: (2017)

Hepatitis B in patients with hematological diseases: An update
por: Coluccio, Chiara, et al.
Publicado: (2017)

Expanding antiviral therapy indications for HBeAg-negative chronic hepatitis B patients with normal ALT and positive HBV DNA
por: Zhou, Jing, et al.
Publicado: (2022)

Impact of hepatitis B virus infection on hepatic metabolic signaling pathway
por: Shi, Yi-Xian, et al.
Publicado: (2016)

Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA
por: Sekiba, Kazuma, et al.
Publicado: (2018)

Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases
por: Kawanaka, Miwa, et al.
Publicado: (2021)

Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure
por: Shinn, Brianna J, et al.
Publicado: (2019)

Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease
por: Khoo, Tiffany, et al.
Publicado: (2021)

Optimal timing of antiviral therapy for patients with malignant tumor who presented with hepatitis B reactivation during chemotherapy and/or immunosuppressive therapy
por: Zou, Xiaofang, et al.
Publicado: (2020)

Update on global epidemiology of viral hepatitis and preventive strategies
por: Jefferies, Meryem, et al.
Publicado: (2018)

Hepatic epithelioid hemangioendothelioma: Update on diagnosis and therapy
por: Kou, Kai, et al.
Publicado: (2020)

Prediction models for development of hepatocellular carcinoma in chronic hepatitis B patients
por: Guo, Jiang, et al.
Publicado: (2021)

Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients
por: Lee, Hye Won, et al.
Publicado: (2016)

Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis
por: Wu, Ya-Li, et al.
Publicado: (2019)

Chemotherapy-induced neurotoxicity in the treatment of gynecological cancers: State of art and an innovative approach for prevention
por: Oneda, Ester, et al.
Publicado: (2021)

Management of hepatitis B and C in special population
por: Kulkarni, Anand V, et al.
Publicado: (2021)

Current evidence on the management of hepatitis B in pregnancy
por: Maraolo, Alberto Enrico, et al.
Publicado: (2018)

Elimination of Hepatitis B: Is It a Mission Possible?
por: Tseng, Tai-Chung, et al.
Publicado: (2017)

Prevention of Hepatitis B Reactivation in Patients Receiving Immunosuppressive Therapy: a Case Series and Appraisal of Society Guidelines
por: Etienne, Samuel, et al.
Publicado: (2022)

Challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings
por: Said, Zeinab Nabil Ahmed, et al.
Publicado: (2022)

Research progress on reactive oxygen species production mechanisms in tumor sonodynamic therapy
por: Dong, He-Qin, et al.
Publicado: (2023)

Treatment of hepatitis B virus infection in children and adolescents
por: Stinco, Mariangela, et al.
Publicado: (2021)

Challenges in the discontinuation of chronic hepatitis B antiviral agents
por: Kaewdech, Apichat, et al.
Publicado: (2021)

Human immune repertoire in hepatitis B virus infection
por: Zhan, Qiao, et al.
Publicado: (2021)

Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy
por: Lee, Hae Lim, et al.
Publicado: (2017)

Fibrosis regression following hepatitis C antiviral therapy
por: Elsharkawy, Aisha, et al.
Publicado: (2022)

Complexities of diagnosis and management of COVID-19 in autoimmune diseases: Potential benefits and detriments of immunosuppression
por: Georgiev, Tsvetoslav, et al.
Publicado: (2020)

Chronic hepatitis B in pregnant women: Current trends and approaches
por: Belopolskaya, Maria, et al.
Publicado: (2021)

Chronic hepatitis B: New potential therapeutic drugs target
por: Leowattana, Wattana, et al.
Publicado: (2022)

Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation
por: Crismale, James F, et al.
Publicado: (2019)

Prevention and treatment of hepatic encephalopathy during the perioperative period of transjugular intrahepatic portosystemic shunt
por: Wang, Lan-Jing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jqe45b1pn1tdts93ndf6nkam89